Metsera, Inc.
MTSR
Peringkat dalam Saham
#2568
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$70.50
Terakhir disinkronkan: 2025-11-14
Kapitalisasi Pasar
$7.33B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
33.60%
Negara
US
Perdagangan Metsera, Inc. (MTSR)
Kategori
Healthcare
Riwayat harga saham Metsera, Inc. (MTSR)
Harga penutupan tertinggi: $72.34 pada 2025-11-01
Harga penutupan terendah: $26.50 pada 2025-01-01
Harga penutupan terendah: $26.50 pada 2025-01-01
Riwayat harga saham Metsera, Inc. dari 2025 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $536.74 | 25.87% |
US
|
|
| $227.23 | 746.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $881.75 | 8.30% |
NL
|
|
| $291.76 | 2.51% |
BE
|
